 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- ||||||| Ahzantive (aflibercept-mrbb) / Amneal, Formycon, Coherus Biosci, Klinge Pharma
Trial completion: MAGELLAN-AMD: Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea (clinicaltrials.gov) - Jun 29, 2023
P3, N=434, Completed, Sponsor: Bioeq GmbH
Active, not recruiting --> Completed
- || FYB203 (aflibercept biosimilar) / Amneal, Eylea (aflibercept intravitreal) / Bayer, Regeneron
$CHRS Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma https://t.co/ejOeN9Fv9V (Twitter) - Jan 9, 2023
- ||||| Ahzantive (aflibercept-mrbb) / Amneal, Formycon, Coherus Biosci, Klinge Pharma
Enrollment closed: MAGELLAN-AMD: Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea (clinicaltrials.gov) - Jun 22, 2022
P3, N=434, Active, not recruiting, Sponsor: Bioeq GmbH
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| Ahzantive (aflibercept-mrbb) / Amneal, Formycon, Coherus Biosci, Klinge Pharma
Trial completion date, Trial primary completion date: MAGELLAN-AMD: Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea (clinicaltrials.gov) - Feb 16, 2022
P3, N=400, Recruiting, Sponsor: Bioeq GmbH
Recruiting --> Active, not recruiting Trial completion date: Oct 2022 --> Jun 2023 | Trial primary completion date: Oct 2021 --> Jun 2022
- || Eylea (aflibercept intravitreal) / Bayer, Regeneron
Review, Journal: Pipeline therapies for neovascular age related macular degeneration. (Pubmed Central) - Oct 3, 2021
Those in the pipeline of VEGF targets include abicipar pegol (Abicipar; Allergan, Coolock, Dublin), OPT-302 (Opthea; OPTHEA limited; Victoria, Melbourne), conbercept (Lumitin; Chengdu Kanghong Pharmaceutical Group, Chengdu, Sichuan), and KSI-301 (Kodiak Sciences, Palo Alto, CA)...Gene therapy present possible longer treatments options as well and are reviewed here. This paper will highlight the past approved medications as well as pipeline therapies for neovascular AMD.
- |||||||||| Ahzantive (aflibercept-mrbb) / Amneal, Formycon, Coherus Biosci, Klinge Pharma
New P3 trial: MAGELLAN-AMD: Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea (clinicaltrials.gov) - Aug 20, 2020
P3, N=400, Recruiting, Sponsor: Bioeq GmbH